Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature Precedings
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • RSS feed
  1. nature
  2. nature precedings
  3. articles
  4. article
Schizophrenia is a TH2 dominant autoimmune disease possibly against acetylcholine receptors of CNS
Download PDF
Download PDF
  • Manuscript
  • Open access
  • Published: 12 March 2012

Schizophrenia is a TH2 dominant autoimmune disease possibly against acetylcholine receptors of CNS

  • Wanchung(Wan-Jiung) Hu1 

Nature Precedings (2012)Cite this article

  • 1168 Accesses

  • 1 Citations

  • 4 Altmetric

  • Metrics details

Abstract

Schizophrenia is a very common psychiatric disorder. However, its etiology and pathogenesis is still unknown. Current theory saying that neurotransmitter imbalance such as serotonin or dopamine only provides limited effectiveness in schizophrenia treatment by drugs changing serotonin and dopamine concentration. Despite of such treatment, majority of schizophrenia patients still have very poor prognosis. Thus, the neurotransmitter imbalance theory is not correct. Here, I propose that schizophrenia is actually a TH2 dominant autoimmune disorder. The candidate of autoantigen could be acetylcholine receptors of CNS. My theory can explain the positive as well as negative symptoms of schizophrenia. By microarray analysis of PBMCS, one-tenth of the total 519 significantly expressed genes are immune-related genes. Among them, TH2 related genes are significantly up-regulated including IL-4, histidine decarboxylase, aldehyde dehydrogenase, CCR9, IgE Fc receptor, GATA2, serotonin receptor, phospholipase A2, and prostaglandin D2 synthase. Besides, TH1 and TH17 related genes are down-regulated including CXCL5, cathepsin C, and neutrophil related S100 binding proteins. The new theory sheds a light to better control this detrimental illness. Anti-inflammatory agents could be used to manage schizophrenia in the near future.

Similar content being viewed by others

Novel drug treatments for schizophrenia

Article 08 January 2026

Overexpression of transmembrane TNFα in brain endothelial cells induces schizophrenia-relevant behaviors

Article 04 November 2022

Intrinsic metabolic and immune impairments in a genetic mouse model of schizophrenia

Article Open access 18 July 2025

Article PDF

Author information

Authors and Affiliations

  1. Academia Sinica,Taiwan https://www.nature.com/nature

    Wanchung(Wan-Jiung) Hu

Authors
  1. Wanchung(Wan-Jiung) Hu
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Wanchung(Wan-Jiung) Hu.

Rights and permissions

Creative Commons Attribution 3.0 License.

Reprints and permissions

About this article

Cite this article

Hu, WJ. Schizophrenia is a TH2 dominant autoimmune disease possibly against acetylcholine receptors of CNS. Nat Prec (2012). https://doi.org/10.1038/npre.2012.6978.1

Download citation

  • Received: 11 March 2012

  • Accepted: 12 March 2012

  • Published: 12 March 2012

  • DOI: https://doi.org/10.1038/npre.2012.6978.1

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • schizophrenia
  • TH2
  • serotonin
  • Histamine
  • autoimmune disorder
  • acetylcholine receptor
  • IgE
Download PDF

Advertisement

Explore content

  • Research articles
  • News & Comment
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Nature Precedings (Nat Preced)

nature.com footer links

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2026 Springer Nature Limited

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing